Cargando…
The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 or...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Psychiatric Pharmacists
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645287/ https://www.ncbi.nlm.nih.gov/pubmed/36405509 http://dx.doi.org/10.9740/mhc.2022.10.309 |
_version_ | 1784826933714878464 |
---|---|
author | Waters, Kristin |
author_facet | Waters, Kristin |
author_sort | Waters, Kristin |
collection | PubMed |
description | Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases. |
format | Online Article Text |
id | pubmed-9645287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association of Psychiatric Pharmacists |
record_format | MEDLINE/PubMed |
spelling | pubmed-96452872022-11-18 The clinical utility of newer antidepressant agents: Understanding the role in management of MDD Waters, Kristin Ment Health Clin Psychopharmacology Pearls Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases. American Association of Psychiatric Pharmacists 2022-11-03 /pmc/articles/PMC9645287/ /pubmed/36405509 http://dx.doi.org/10.9740/mhc.2022.10.309 Text en © 2022 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Psychopharmacology Pearls Waters, Kristin The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
title | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
title_full | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
title_fullStr | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
title_full_unstemmed | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
title_short | The clinical utility of newer antidepressant agents: Understanding the role in management of MDD |
title_sort | clinical utility of newer antidepressant agents: understanding the role in management of mdd |
topic | Psychopharmacology Pearls |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645287/ https://www.ncbi.nlm.nih.gov/pubmed/36405509 http://dx.doi.org/10.9740/mhc.2022.10.309 |
work_keys_str_mv | AT waterskristin theclinicalutilityofnewerantidepressantagentsunderstandingtheroleinmanagementofmdd AT waterskristin clinicalutilityofnewerantidepressantagentsunderstandingtheroleinmanagementofmdd |